$11.300
+0.329 (+2.91%)Zum Schluss
NVNO-News
NVNO-Events
enVVeno Medical Files $100M Mixed Securities Shelf
enVVeno Medical files $100M mixed securities shelf
enVVeno Approved to Proceed with enVVe Pivotal Study
"The second quarter represented a defining milestone for enVVeno, as we got the approval to move forward with the pivotal study for enVVe, our non-surgical replacement venous valve. enVVe has the potential to completely change the treatment trajectory for the 3 million U.S. patients in the U.S. that suffer from severe, deep venous CVI and have no effective treatment options," commented Rob Berman, CEO. "As we enter the second half of 2026, our focus is squarely on executing the TAVVE pivotal study, getting our clinical sites up and running, and treating the first patients."
Company Reports Q2 Cash Burn of $3.4M
Cash burn for the second quarter was $3.4M, consistent with the Company's projected cash burn rate of approximately $3M to $4M per quarter. The Company anticipates that its cash burn rate will likely increase to between $4M and $5M per quarter in the second half of 2026 as the TAVVE study begins enrolling patients.
enVVeno Medical Secures U.S. Patent, CEO Highlights Market Potential
enVVeno Medical announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Berman discussed the Company's recent news announcing the issuance of the first U.S. Patent covering the company's enVVe system, further expanding its intellectual property portfolio and laying the groundwork to dominate the large and untapped replacement venous valve market. "Receiving a foundational U.S. patent while simultaneously advancing the first FDA-approved pivotal trial for a non-surgical replacement venous valve are both important fundamental parts of our strategy to build shareholder value," said Robert Berman, Chief Executive Officer of enVVeno Medical. "In this discussion, we explain why we believe these milestones significantly strengthen our long-term competitive position, reinforce the barriers to entry around our technology, and position the Company to pursue what we believe is a substantial commercial opportunity."
enVVeno Medical Secures U.S. Patent No. 12,575,932
enVVeno Medical announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe transcatheter replacement venous valve system for the treatment of venous disease. The issued patent covers key components of the enVVe system, including the enVVe valve, valve support frame, crimping system, and delivery system, as well as methods for use in treating patients with deep venous insufficiency. The enVVe system is the transcatheter evolution of the clinically proven surgical device, designed to restore proper one-way blood flow in the deep veins of the leg.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.